At its Oct. 12, 2026 semiannual results briefing, Zhijiang Biological said
overseas markets are a strategic priority. In 1H2026 the company secured seven
new international certifications. With ongoing deliveries of overseas orders,
expanded CE/FDA coverage and deeper distribution channels, it expects overseas
revenue to increase gradually, targeting Europe, Africa, the Middle East and
Southeast Asia.